BIIB News 305.69 10/16/2014 04:33:00 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 305.69 $BIIB

IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 26.41 (+4.29), BIIB: 305.69 (+4.11), KITE: 31.85 (+0.55), FWP: 17.50 (-1.49), XENE: (), ATRA: (), VBAY: (), GWB: 18.00 (+0.10)

Major Averages Pare Losses, Then Head Lower Again
at Investor's Business Daily - Wed Oct 15, 11:01AM CDT
Stocks headed lower again in late-morning trade after paring steep early losses sparked by weak economic data. The S&P 500 and Dow industrials sank 1.5% each, while the Nasdaq was down 1.3%. The tech-heavy index had earlier narrowed its deficit to...
AMBA: 38.60 (+2.94), BIIB: 305.69 (+4.11), CAVM: 43.12 (+3.25), NTES: 88.99 (+3.13), NXPI: 58.61 (+2.03), INTC: 31.27 (-0.87)

Biogen Idec and Gretchen Rubin Unveil MS Blueprint(TM), a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
Business Wire - Wed Oct 15, 7:01AM CDT
Living with a chronic condition like multiple sclerosis (MS) can be overwhelming for individuals and caregivers who have to balance the challenges of everyday life and work while juggling regular doctors' visits and medications. To support people living with MS, Biogen Idec (NASDAQ:BIIB) has launched MS Blueprint(TM), a new program that encourages those impacted by MS to focus on activities that may bring joy to their lives every day. By visiting MSBlueprint.com, people can set goals, create personalized MS Blueprints, and take small steps toward a more positive life.
BIIB: 305.69 (+4.11)

IBD 50: Medical, Internet Companies Top Q3 Estimates
at Investor's Business Daily - Mon Oct 13, 6:15PM CDT
Health care and Internet companies are expected to have some of the strongest third-quarter profit gains in the IBD 50. The consensus analyst estimates for medical leaders Gilead Sciences (GILD) and Lannett (LCI) exceed 200% growth. The June-quarter...
AMBA: 38.60 (+2.94), BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), VIPS: 185.68 (+8.98), YY: 72.40 (+2.93), SWKS: 49.60 (+0.69), FB: 73.21 (-0.38), AKRX: 34.95 (-0.31), KSU: 115.57 (+0.43), SLXP: 132.42 (-1.16), ATHM: 45.12 (+2.63), LCI: 40.30 (-0.36), ABC: 76.02 (-0.61), GILD: 96.16 (-1.02), AVGO: 72.55 (+0.53)

Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Isis Pharmaceuticals (ISIS) announced positive results from phase II studies on ISIS-SMNRx.
MDVN: 89.63 (-1.68), BIIB: 305.69 (+4.11), ISIS: 38.97 (+2.13), LGND: 46.28 (+0.45)

SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 4.25% Loss
Comtex SmarTrend(R) - Mon Oct 13, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.99 to a high of $315.75. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $312.00 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.69 (+4.11)

IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 26.41 (+4.29), BIIB: 305.69 (+4.11), FWP: 17.50 (-1.49), KITE: 31.85 (+0.55), XENE: (), MRK: 54.73 (-1.60), CFG: 21.85 (-0.60), ZAYO: (), ATRA: (), TEVA: 50.09 (+0.19), VBAY: (), GWB: 18.00 (+0.10)

Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire
PR Newswire - Mon Oct 13, 7:30AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Arrowhead Research Corp. (NASDAQ: ARWR), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), HCA Holdings, Inc. (NYSE: HCA) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7111-100free.
HCA: 64.84 (-2.14), BIIB: 305.69 (+4.11), ARWR: 6.47 (+0.59), SHPG: 170.49 (-74.08), SLXP: 132.42 (-1.16)

1 Huge Risk Facing This Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 12, 11:02AM CDT
Source: GW Pharmaceuticals The prospects for medical marijuana are incredibly intriguing. According to a Medical Marijuana Markets report in 2011, the market for medical marijuana may surge from $1.7 billion in that same year to as much as $9...
BIIB: 305.69 (+4.11), GWPH: 61.55 (-3.65), SNY: 51.50 (-0.75), NVS: 86.22 (-0.65)

Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe
Thomson Reuters ONE - Thu Oct 09, 2:01PM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that Biogen Idec has submitted a Marketing Authorisation Application (MAA) for Elocta (rFVIIIFc) to the European Medicines Agency (EMA). Sobi has an exclusive opt-in right to assume final development and commercialisation of Elocta in Europe, Russia, the Middle East and Northern Africa.
BIIB: 305.69 (+4.11)

Global Biological Drugs Market Outlook 2020
M2 - Thu Oct 09, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv5tsf/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market. Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/sv...ical_drugs
BIIB: 305.69 (+4.11), ABT: 40.01 (-1.05), BAX: 68.34 (-0.52), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), BMY: 48.96 (+0.04), NVS: 86.22 (-0.65)

CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Wed Oct 08, 3:01PM CDT
Second paragraph, first sentence of release dated September 25, 2014 should read: Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. (instead of Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 9:00 am ET.).
BIIB: 305.69 (+4.11)

5 States Expected to See the Biggest Increase in Alzheimer's Disease
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 05, 10:07AM CDT
Source: Centers for Disease Control and Prevention. Cancer and heart disease may be far more prevalent killers, but Alzheimer's disease is certainly no ailment to overlook, considering that it's the eighth leading cause of death in the United...
BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), PFE: 28.19 (-0.27), LLY: 62.87 (-0.27)

The Next Blue-Chip Stocks: Biogen Idec
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 04, 10:32AM CDT
Becoming the next blue chip stock isn't easy, especially in a high risk, high reward sector like biotech. But once you get to be as big as Biogen Idec , blue chip status is the next obvious step. BIIB data by YCharts Solid revenue...
BIIB: 305.69 (+4.11), AMGN: 130.90 (-1.30)

Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 305.69 (+4.11), PRGO: 145.85 (-1.33), ABAX: 48.07 (+0.20), HAE: 35.62 (+0.16)

Insider Trading Alert - BIIB, RKUS And PF Traded By Insiders
at The Street - Fri Oct 03, 9:30AM CDT
Stocks with insider trader activity include BIIB, RKUS and PF
BIIB: 305.69 (+4.11), PF: 32.12 (-0.56), RKUS: 11.68 (+0.37)

Global Cancer Monoclonal Antibodies Market & Pipeline Insight 2014
M2 - Fri Oct 03, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l88677/global_cancer) has announced the addition of the "Global Cancer Monoclonal Antibodies Market & Pipeline Insight" report to their offering. A significant amount of research is being carried out currently to improve the level of potency of monoclonal antibodies. Consequently, a relatively new approach has been indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers, mostly monoclonal antibodies. However, still a lot of work needs to be done in this arena. Though the monoclonal antibodies have already emerged as significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful. Additionally, the pharma companies are also researching on ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body's immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions. It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies. The future of mAbs for cancer continues to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human cells there is still significant work which needs to be done. Global Cancer Monoclonal Antibodies Market & Pipeline Insight Report highlights: - Cancer Monoclonal Antibodies Market Overview - Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook - Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country - Cancer Monoclonal Antibodies in Pipeline: 605 - Majority Cancer Monoclonal Antibodies Preclinical Phase: 258 - Marketed Cancer Monoclonal Antibodies: 34 - Cancer Monoclonal Antibodies Patent Analysis Key Topics Covered: 1. Introduction to Monoclonal Antibodies 2. Types of Monoclonal Antibodies 3. Mechanisms of Monoclonal Antibodies 4. Need for Monoclonal Antibodies for Cancer Treatment 5. Cancer Monoclonal Antibodies Market Overview 6. Cancer Monoclonal Antibodies Market Dynamics 7. Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country 8. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 9. Suspended & Discontinued Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country 10. Competitive Landscape - Abbvie - Amgen - Bayer HealthCare - Biogen Idec - Eli Lilly - Genmab - Gilead Sciences - GlaxoSmithKline - Novartis - Pfizer - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/l8...bal_cancer
BIIB: 305.69 (+4.11), GILD: 96.16 (-1.02), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), NVS: 86.22 (-0.65)

Top Fund Buys: Chipotle, Allergan, Jazz, Gilead
at Investor's Business Daily - Thu Oct 02, 5:25PM CDT
While the stock market clocked a slight gain in the last full month of summer, the uptrend was under pressure during the second half of September. Managers of top-performing funds the past three months continued to add shares of medical issues during...
FDX: 153.82 (+0.10), BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), FB: 73.21 (-0.38), SLXP: 132.42 (-1.16), WSM: 63.71 (-0.42), CELG: 86.55 (+0.07), LUV: 30.02 (+0.02), AGN: 177.59 (-4.40), DLTR: 55.24 (-0.64), GILD: 96.16 (-1.02), CMG: 647.38 (-3.79), JAZZ: 146.31 (+2.58), COST: 124.30 (-1.95), CVS: 78.99 (-1.69), ULTA: 110.28 (-1.68), UNP: 99.70 (-0.46)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 141

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 15

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 80

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 107

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 93

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 61

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 135

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading

Top 5 Most Recently Viewed Articles

Blue Moon Metals Secures C$60 Million for Strategic Growth

Updated Category News Views 164

Blue Moon Metals Announces Major Financing Initiative Blue Moon Metals Inc. (TSXV: MOON; OTCQX: BMOOF), based in Toronto, is embarking on an exciting new phase as the company has entered a letter agreement with key financial partners. These partners include Scotiabank and Canaccord Genuity Corp., who are playing a pivotal role as joint bookrunners in this financial...

Continue Reading
Theravance Biopharma Engages Investors at Upcoming Conference

Updated Category News Views 330

Theravance Biopharma's Upcoming Investor Conference Participation Theravance Biopharma, Inc. (NASDAQ: TBPH) is eager to actively engage with the investment community during a significant event. The company is set to take part in a Fireside Chat at an upcoming health conference, where it will discuss its ongoing projects and recent advancements in its pipeline. This event...

Continue Reading
Bright Green Partners with Benuvia for Raw Material Supply

Updated Category News Views 238

Bright Green Partners with Benuvia Operations Bright Green Corporation (Nasdaq: BGXX) has announced an important partnership through a letter of intent to provide its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leading name in pharmaceutical cannabinoids. This collaboration highlights Bright Green's dedication and capability to...

Continue Reading
EHang's Progress and Financial Results: Navigating Change

Updated Category News Views 389

EHang Reports Its Third Quarter Financial Performance EHang Holdings Limited (NASDAQ: EH), a leader in advanced air mobility, has recently released its unaudited financial results for the third quarter. The company continues to strive towards maintaining its full-year revenue guidance of RMB500 million. In this article, we will highlight key operational and financial...

Continue Reading
Osisko Development Unveils Comprehensive Insights on Cariboo Gold

Updated Category News Views 258

Osisko Development Releases Technical Report for Cariboo Gold Project Osisko Development Corp. has taken a significant step in its journey to develop the Cariboo Gold Project by filing a comprehensive technical report. This report, prepared in line with the National Instrument 43-101 guidelines, highlights the feasibility study results for this promising site. The Cariboo...

Continue Reading